GPATCH4

Across TCGA pan-cancer cohorts, GPATCH4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GPATCH4 data layer compared with 28 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GPATCH4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated GPATCH4 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

CCRCC, LUAD, and LSCC are the cancer types where GPATCH4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Tertile	II,III,IV	0.408	0.909	.002	36	view →
LUAD	DFS	Median	III,IV	0.797	0.222	<.001	25	view →
LSCC	DFS	Tertile	II,III,IV	0.896	0.504	.011	19	view →
PDAC	DFS	Quartile	All	0.484	0.214	.009	6	view →
HNSC	DFS	Quartile	III,IV	0.614	0.885	.021	2	view →
GBM	OS	Median	All	0.658	0.383	.010	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GPATCH4–CCRCC (OS)

Open the CCRCC breakdown →